Sponsor Pipeline

AbbVie Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
169
Active Trials
102
Recruiting
55
Phase 3
10
Disease Areas
83
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-10 NCT07490301
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With…
Recruitment opened
2026-06-10 NCT07490301
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With…
Trial sites expanded: 0 -> 9 locations
2026-06-06 NCT05125302
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the…
Trial sites expanded: 124 -> 129 locations
2026-06-05 NCT06849791
A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult…
Trial completed
2026-06-05 NCT06849791
A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult…
date change Primary completion pushed: 2026-03 -> 2026-05-08
2026-06-05 NCT06849791
A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult…
date change Completion pushed: 2026-03 -> 2026-05-08
2026-06-05 NCT04189614
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With…
Trial terminated
2026-06-05 NCT04189614
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With…
critical why stopped: null → "Strategic considerations"
2026-06-05 NCT07566130
A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of…
Trial completed
2026-06-03 NCT05445778
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in…
date change Primary completion moved earlier: 2032-05 -> 2027-04
2026-06-03 NCT06568939
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin…
Trial sites expanded: 64 -> 71 locations
2026-06-03 NCT05753501
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves…
Trial arms changed: 3 -> 4
2026-06-03 NCT07306832
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves…
Recruitment opened
2026-06-03 NCT07306832
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves…
Trial sites expanded: 0 -> 5 locations
2026-06-03 NCT07306832
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves…
date change Completion pushed: 2028-04 -> 2030-03
2026-06-03 NCT06953960
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone…
Enrollment increased: 130 -> 199 participants
2026-06-03 NCT06953960
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone…
Trial sites expanded: 32 -> 46 locations
2026-06-03 NCT06772623
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab…
Trial sites expanded: 92 -> 96 locations
2026-06-02 NCT06575192
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast…
Primary endpoint(s) modified
2026-06-02 NCT06575192
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast…
Enrollment reduced: 783 -> 264 participants
Showing 20 of 83 changes detected in the last 30 days.
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-05-27 NCT07607964 A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness… Phase 1 Recruiting
2026-05-22 NCT07600762 A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib… Phase 1 Not Yet Recruiting
2026-05-22 NCT07604545 A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in… Not Yet Recruiting
2026-05-22 NCT07604558 A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves… Phase 1 Not Yet Recruiting
2026-05-20 NCT07599670 A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenous… Phase 1/2 Not Yet Recruiting
2026-05-20 NCT07599761 A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult… Phase 1 Recruiting
2026-05-18 NCT07592273 Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With… Phase 2/3 Recruiting
2026-05-14 NCT07587008 Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult… Phase 1 Not Yet Recruiting
Active Trials by Phase
Phase 4
4
Phase 3
46
Phase 2/3
9
Phase 2
26
Phase 1/2
8
Phase 1
42
Not specified
34
Active Trials — top 25 of 169
NCT IDTitleConditionStatus
Phase 4
NCT07044687 Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in… Acute Myeloid Leukemia Recruiting
NCT07122583 A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh… Non-Surgical Fat Reduction Active, Not Recruiting
NCT07186595 A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult… Mid Face Volume Deficit Active, Not Recruiting
NCT05821855 A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma… Open-angle Glaucoma Active, Not Recruiting
Phase 3
NCT05889182 A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in… Hidradenitis Suppurativa Recruiting
NCT07284381 A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear… Dry Eye Disease Recruiting
NCT06461897 A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral… Atopic Dermatitis Recruiting
NCT06428019 A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants… Chronic Lymphocytic Leukemia Recruiting
NCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD AMD Recruiting
NCT06012240 A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and… Alopecia Areata Recruiting
NCT05711394 A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant… Episodic Migraine Recruiting
NCT06100744 A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves… Juvenile Psoriatic Arthritis Recruiting
NCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis… Atopic Dermatitis Recruiting
NCT05609630 Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in… Juvenile Idiopathic Arthritis Recruiting
NCT07007065 Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and… Neovascular Age-related Macular Degeneration Recruiting
NCT05995353 A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and… Crohn's Disease Recruiting
NCT06575192 Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast… Breast Reconstruction Recruiting
NCT06822738 A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation… Primary Open Angle Glaucoma Recruiting
NCT06417775 Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult… Migraine Recruiting
NCT04777357 A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in… Depression Recruiting
NCT06332534 Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric… Crohn's Disease Recruiting
NCT06734351 A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult… Mid Face Volume Deficit Recruiting
NCT06810505 A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity… Chronic Migraine Recruiting
NCT07071519 A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative… Ulcerative Colitis Recruiting
NCT05125302 Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the… Migraine Recruiting
View all 169 active AbbVie trials with filters →
Disease Areas
Get alerts when AbbVie's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free